Additionally, we confirmed that the olaparib treatment increased CRY1 and the phosphorylation of AKT, which was suppressed by the bevacizumab treatment, using another clear cell carcinoma cell line, OVTOKO. The gene discussed is AKT1; the disease is clear cell adenocarcinoma.